Transcription factors and neoplasia: Vistas in novel drug design

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 949-961

  Karamouzis, Mihalis V ^a   Gorgoulis, Vassilis G ^b   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; AJOENE; AMINOTHIOL; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DISTAMYCIN A; FR 901228; FULVESTRANT; LEPTOMYCIN B; MOFAROTENE; MUSTARD GAS; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; OXAMFLATIN; PACLITAXEL; PARTHENOLIDE; PICEATANNOL; RETINOID; RITUXIMAB; STAUROSPORINE; TAMOXIFEN; TRABECTEDIN; TRANSCRIPTION FACTOR; TRICHOSTATIN A;

ANIMAL CELL; APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; CELL INTERACTION; CYTOARCHITECTURE; DRUG DESIGN; DRUG TARGETING; GENE EXPRESSION REGULATION; GENETIC REGULATION; GENETIC TRANSCRIPTION; MOLECULAR RECOGNITION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 0036094708     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Therapeutic modulation of transcription factor activity
2. Transcription factor modulating agents: Precision and selectivity in drug design
3. Cellular and molecular pharmacology of antiestrogen action and resistance
4. How can we use our growing understanding of gene transcription to discover effective new medicines?
5. Structure-based drug design
6. Recent advances in structure-based rational drug design
7. Transcription factor mutations and human disease
8. Transcription factors
9. RNA polymerase II holoenzyme and transcriptional regulation
10. Mechanisms of transcription complex assembly
11. Mediator complexes and transcription
12. Transcription factors: Structural families and principles of DNA recognition
13. Transcription factors: Structure, function and implication in malignant growth
14. Homeobox genes in normal and malignant cells
15. The homeodomain-containing proteins: An update on their interacting partners
16. The structure of the nuclear hormone receptors
17. Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription
18. Embryonic stem (ES) cells lacking functional c-jun: Consequences for growth and differentiation, AP-1 activity and tumorigenicity
19. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity
20. Mechanisms of transcription activation: Differences and similarities between yeast. Drosophila, and man
21. Multiple steps in the regulation of transcription-factor level and activity
22. Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors
23. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions
24. Role of covalent modifications of histories in regulating gene expression
25. Histone acetylases and deacetylases in cell proliferation
26. Opening the way to gene activity
27. Hendzel a transcriptional coactivator and acetyltransferase
28. Retinoblastoma protein recruits histone deacetylase to repress transcription
29. Nuclear hormone receptors and gene expression
30. New insights into receptor ligand binding domains from a novel assembly assay
31. Role of coactivators and corepressors in steroid and nuclear receptor signaling: Potential markers of tumor growth and drug sensitivity
32. Transcriptional cross-talk, the second mode of steroid hormone receptor action
33. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
34. Stimulation of RAR α activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK 7
35. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
36. myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course
37. Oncogenic activity of the c-Myc protein requires dimerization with Max
38. Specific DNA binding by c-Myb: Evidence for a double helix-turn-helix-related motif
39. Signal transduction and the Ets family of transcription factors
40. Translocations, master genes, and differences between the origins of acute and chronic leukemia
41. Chromosomal translocations in human cancer
42. Transcription factors and translocations in lymphoid and myeloid leukemia
43. Exploring (novel) gene expression during retinoid-induced maturation and cell death of acute promyelocytic leukemia
44. The translocation t(8;16) (p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein
45. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia
46. Transcription factor-based drug design in anticancer drug development
47. New insights into the role of nuclear factor-KB in cell growth regulation
48. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
49. Structure of the NF-κB p50 homodimer bound to DNA
50. The developmentally-regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma
51. Targeting gene transcription: A new strategy to down-regulate c-erbB-2 expression in mammary carcinoma
52. Hsp90: Chaperoning signal transduction
53. Antagonistic and agonistic effects of tamoxifen: Significance in human cancer
54. Tamoxifen to raloxifene and beyond
55. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions
56. Tumor suppressor genes
57. Retinoblastoma protein switches the E2F site from positive to negative element
58. Binding and suppression of the Myc transcriptional activation domain by p107
59. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1
60. Genotoxic and non-genotoxic pathways of p53 induction
61. p53 from complexity to simplicity: Mutant p53 stabilization, gain-of-function, and dominant-negative effect
62. Regulation of p53 stability
63. Regulation and function of the p53-related proteins: Same family, different rules
64. Molecular mechanisms of retinoid action
65. Retinoids in chemoprevention and differentiation therapy
66. A review of cancer chemopreventive agents
67. Elevated retinoic acid receptor β(4) protein in human breast tumor cells with nuclear and cytoplasmic localization
68. Cell division gatekeepers identified
69. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation
70. Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1
71. rasmutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions
72. Functional analysis of the human cyclin D2 and cyclin D3 promoters
73. Antisense therapy in oncology: New hope for an old idea?
74. Post-transcriptional gene silencing by double-stranded RNA
75. RNA interference-2001
76. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
77. Novel anticancer agents in development: Exciting prospects and new challenges
78. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
79. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
80. P53-targeted drugs: Intelligent weapons in the tumor-suppressing arsenal
81. Enlisting Combichem to fight cancer
82. The keys to chemical genomics
83. Molecular mechanisms of antiestrogen action in breast cancer
84. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor
85. Activation of the human estrogen receptor by the antiestrogens ICI 182,780 and tamoxifen in yeast genetic systems: Implications for their mechanism of action
86. A therapeutic target for hormone-independent estrogen receptor-positive breast cancers
87. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: Type II estrogen binding sites and tubulin
88. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid
89. Histone deacetylase inhibitors as new cancer drugs
90. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
91. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor β type II receptor expression in human breast cancer cells
92. Pardee Activation of the p21WAF1/C1P1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites
93. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
94. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs
95. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by 1κBα super-repressor and parthenolide
96. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase
97. Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family
98. Nuclear factor-κB-dependent regulation of p 53 gene expression induced by daunomycin genotoxic drug
99. Activation of NF-κB by antineoplastic agents. Role of protein kinase C
100. Ajoene a compound of garlic, induces apoptosis in human promyeloleukemic cells, accompanied by generation of reactive oxygen species and activation of nuclear factor KB
101. Sulphur mustards inhibit binding of transcription factor AP2 in vitro
102. Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements
103. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA
104. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
105. IκB kinases α and β show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin
106. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs
107. Distinct mechanisms of STAT phosphorylation via the interferon-α/β receptor. Selective inhibition of STAT3 and STAT5 by piceatannol
108. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
109. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells
110. Down-regulation of mitochondrial gene expression by the anti-tumor arotinoid mofarotene (Ro 40-8757)
111. Arotinoid mofarotene (RO40-8757) up-regulates p 21 and p27 during growth inhibition of pancreatic cancer cell lines
112. Reaching the global minimum in docking simulations: A Monte Carlo energy minimization approach using Bezier splines
113. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking
114. Wang a Monte Carlo simulation approach to the molecular docking problem
115. Rational discovery of novel nuclear hormone receptor antagonists
116. Computational protein design
117. Positive selection system to screen for inhibitors of human immunodeficiency virus-1 transcription
118. Towards an understanding of complex protein networks
119. Discovering novel chemotherapeutic drugs for the third millennium